Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: Keith Hankin who wrote (599)	1/14/1998 6:53:00 PM
From: William Marsh	Respond to of 1728

I think AFFX, INCY and other like firms are selling shovels in the gold rush - very high potential returns without the risk or regulatory hassles of drug development. This market seems to be divided between technologies which automate the collection of data (AFFX, SYNTANI, HYSEQ) and technologies which manipilute the data (INCY). It seems INCY and AFFX are starting to fish in each ponds, though.

To: Keith Hankin who wrote (599)	1/19/1998 6:01:00 PM
From: tonygt19	Read Replies (1) \| Respond to of 1728

In biotechnology the companies that sell the technology will always make more money over time, short term or long term, but especially short term than those after the answers. But none of them are good short term investments unless you can deal in split seconds to take advantage of ridiculous implications like Geron's "discovery of an anti-aging enzyme" to short its stock after a 50% overnight increase. Biotech has suffered terribly from uninformed hype. It's true value is still unrealized and several years away. Affymetrix is not selling technology it is literally giving it away in order to monopolize what will be an unbelievably lucrative diagnostic revolution. But until they actually have their $150,000 Hybridization and Detection Equipment in hospitals worldwide and are selling their genechips hand over fist to tell doctors what's going on inside their patients Affymetrix won't make much money at all.